"The voice for cancer physicians and their patients in Massachusetts."

  • Home
  • Resources
  • FDA Approvals
  • FDA grants accelerated approval to rucaparib (Rubraca) for BRCA-mutated metastatic castration-resistant prostate cancer

FDA grants accelerated approval to rucaparib (Rubraca) for BRCA-mutated metastatic castration-resistant prostate cancer

19 May 2020 7:06 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration granted accelerated approval to rucaparib (RUBRACA, Clovis Oncology, Inc.) for patients with deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. Read full press release.

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software